Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $118K invested in Sonnet BioTherapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.11% less ownership
Funds ownership: 0.37% → 0.26% (-0.11%)
25% less capital invested
Capital invested by funds: $158K → $118K (-$40.3K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$57.8K |
| 2 |
VF
Virtu Financial
New York
|
+$18.2K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.05K |
| 4 |
Citigroup
New York
|
+$67 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$76K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$51.2K |
| 3 |
Morgan Stanley
New York
|
-$188 |
| 4 |
BlackRock
New York
|
-$121 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$78 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $64.1K | +$57.8K | +4,307 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $27.4K | – | – | – |
|
|
VF
3
Virtu Financial
New York
| $20K | +$18.2K | +1,355 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $5.07K | +$1.05K | +78 | +30% |
|
|
5
BlackRock
New York
| $967 | -$121 | -9 | -12% |
|
|
6
Citigroup
New York
| $71 | +$67 | +5 | New |
|
7
Wells Fargo
San Francisco,
California
| $41 | – | – | – |
|
|
8
Morgan Stanley
New York
| $11 | -$188 | -14 | -93% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $11 | +$13 | +1 | New |
|
|
PWMG
10
Private Wealth Management Group
Princeton,
New Jersey
| $6 | – | – | – |
|
|
11
Renaissance Technologies
New York
| – | -$76K | -5,469 | Closed |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$51.2K | -3,681 | Closed |
|
|
13
Osaic Holdings
Scottsdale,
Arizona
| – | -$78 | -6 | Closed |
|
14
JP Morgan Chase
New York
| – | -$33 | -2 | Closed |
|
SONN Hedge Fund Activity: Q1 2024 in Review
9 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2024, worth a combined $118K — down 25% from $158K a quarter earlier.
Fund positioning in SONN was balanced in Q1 2024: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $57.8K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $76K sold.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $118K of Sonnet BioTherapeutics stock for Q1 2024, down 25% quarter-over-quarter.
- 4 funds opened new Sonnet BioTherapeutics positions in Q1 2024 and 4 closed out, a net change of 0 holders.
- The largest Sonnet BioTherapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $57.8K added.
- The largest Sonnet BioTherapeutics seller in Q1 2024 was Renaissance Technologies, an estimated $76K sold.
Based on aggregated 13F filings for Q1 2024.